OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy

J Clin Oncol. 2006 Nov 10;24(32):5176-7; author reply 5177. doi: 10.1200/JCO.2006.07.5630.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Data Interpretation, Statistical
  • Disease-Free Survival
  • Drug Administration Schedule
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Neoplasm Metastasis
  • Organoplatinum Compounds / administration & dosage*
  • Organoplatinum Compounds / adverse effects
  • Organoplatinum Compounds / therapeutic use
  • Pulse Therapy, Drug
  • Sample Size
  • Survival Analysis
  • Treatment Outcome

Substances

  • Organoplatinum Compounds
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol